24 Aug Amani Gillette: An entrepreneur’s journey to improve cancer care
Amani Gillette
Cellular therapies, such as Chimeric Antigen Receptor (CAR) T-cell therapy and stem cell therapy, are promising new avenues in cancer treatment and regenerative medicine. Many of these therapies are still in their infancy, requiring further development to increase efficacy and accessibility.
This is where Amani Gillette, founder of SeLight, LLC, is focusing her efforts. SeLight is currently developing a device that could revolutionize cell manufacturing by allowing researchers and clinicians to screen cell health and fitness before manufacturing. The technology won a Wisconsin Alumni Research Foundation (WARF) Innovation Award in 2018.
Morgridge Communications sat down with Amani — who is also a postdoctoral research associate at the Morgridge Institute for Research, in the lab of Melissa Skala — to learn more about the company, the science, and its impact.